IP Verse

Methods For Dose Initiation Of Aripiprazole Treatments - EP4125903B1

PatentPatent Analysis

EP4125903

OTSUKA PHARMACEUTICAL
Application Number
EP21720012A
Filing Date
Apr 1, 2021
Status
Granted And Under Opposition
Sep 6, 2024
Grant Date
Oct 9, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2767285B2
EP4069254B1
EP2841431B2

Bibliography

The patent EP4125903B1 was granted to Otsuka Pharmaceutical on Oct 9, 2024 following the initial filing on Apr 1, 2021 under the application number EP21720012A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 9, 2025ADMISSIBLE
ZENTIVAJul 9, 2025ADMISSIBLE
RUMIJul 8, 2025ADMISSIBLE
SANDOZJul 4, 2025ADMISSIBLE
DR SCHONJul 1, 2025ADMISSIBLE
MAIWALDJul 1, 2025ADMISSIBLE
STADA ARZNEIMITTELJul 1, 2025ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents